Skip to Content
Search Menu

EHA 2026: Combination Therapy Provides Durable QoL and Physical Function Benefits in Treatment-Naïve CLL

At EHA 2026, results from the phase 3 AMPLIFY trial showed that time-limited acalabrutinib-based combinations were associated with greater and more durable improvements in quality of life and physical functioning than chemoimmunotherapy.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Related

Panagiotis Baliakas

EHA 2026: Germline Testing Beyond Family History in AML and MDS

/ Panagiotis Baliakas
EHA26 Play the Video 1:46
Mika Kontro

EHA 2026: Novel Cell Therapy Approaches in AML

/ Mika Kontro
AMLEHA26 Play the Video 1:56
Caroline Arvé

EHA 2026: MRD Predicts Post-Transplant Relapse in High-Risk MDS and AML

/ Caroline Arvé
AMLEHA26 Play the Video 4:11
Astrid Hundeboell Torpe

EHA 2026: Teclistamab Outcomes in High-Risk Extramedullary Myeloma

/ Astrid Hundebøll Torpe
EHA26Myeloma Play the Video 2:08
Dr. Lei Fan

EHA 2026: LB2501 Advances In Vivo CAR-T with Single-Infusion Treatment

/ Lei Fan
CAR-TEHA26Lymphoma Play the Video 3:49
Maren Poulsgaard Jørgensen

EHA 2026: Increased Risk of Psychotropic Drug Use Observed in Patients with Mastocytosis

/ Maren Poulsgaard Jørgensen
EHA26 Play the Video 2:41
Astrid Hundeboell Torpe

EHA 2026: Low-Dose Venetoclax Demonstrates Durable Responses in Relapsed/Refractory t(11;14) Multiple Myeloma

/ Astrid Hundebøll Torpe
EHA26Myeloma Play the Video 3:03
Andreas Glenthøj

EHA 2026: Advances in Sickle Cell Disease and Beta-Thalassemia

/ Andreas Glenthøj
EHA26Sickle cell anaemia Play the Video 2:27
Stephan Stilgenbauer

EHA 2026: Tacabrutideg Shows High Response Rates and Durable Outcomes in High-Risk Relapsed/Refractory CLL

/ Stephan Stilgenbauer
CLLEHA26 Play the Video 3:02
Back to top